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Abstract
Introduction:Mast cells are the primary effector cells of allergy. This study aimed
at characterizing human peripheral blood-derived mast cells (PBdMC) from
peanut allergic and non-allergic subjects by investigating whether the molecular
and stimulus-response profile of PBdMC discriminate between peanut allergic and
healthy individuals.
Methods: PBdMC were generated from eight peanut allergic and 10 non-allergic
subjects. Themolecular profile (cell surface receptor expression) was assessed using
flow cytometry. The stimulus-response profile (histamine release induced by
secretagogues, secretion of cytokines/chemokines and changes in miRNA
expression following anti-IgE activation) was carried out with histamine release
test, luminex multiplex assay and miRNA arrays.
Results: Expression of activating receptors (FceRI, CD48, CD88,CD117, andC3aR) on
PBdMC was not different among peanut allergic and non-allergic subjects. Likewise,
inhibitory receptors (CD32,CD200R,CD300a, andsiglec-8)displayedcomparable levels
of expression. Both groups of PBdMCwere unresponsive to substance P, compound 48/
80 and C5a but released comparable levels of histamine when stimulated with anti-IgE
andC3a. Interestingly, among the secreted cytokines/chemokines (IL-8, IL-10, IL-13, IL-
23, IL-31, IL-37,MCP-1,VEGF,GM-CSF)PBdMCfrompeanutallergic subjects showed
a different secretion pattern of IL-31 compared to non-allergic subjects. Investigating
miRNAexpression from resting or activatedPBdMCrevealed no significantly difference
between peanut allergic and non-allergic subjects.
Conclusion: The molecular and stimulus-response profile revealed that PBdMC
from peanut allergic subjects differently express IL-31 compared to non-allergic
subjects. However, since only one altered parameter was found among 893
investigated, it is still questionable if the pathophysiological mechanisms of peanut
allergy are revealed in PBdMC.
Introduction
Peanut allergy is estimated to affect 0.2% of the European
population, is rarely outgrown, and is the common culprit
food most frequently causing a severe life-threatening
allergic reaction following exposure to trace amounts [1–3].
The primary effector cell of food allergy is the IgE-sensitized
tissue-resident mast cell, which, due to its mediator release,
cause the clinical symptoms observed during a peanut
allergic reaction such as oral swelling and itching, nausea,
416 © 2018 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
stomach cramps, urticaria, diarrhea, hives, and low blood
pressure [4]. Upon allergen cross-linkage of allergen-specific
IgE bound to high affinity IgE receptors (FceRI), mast cells
release histamine, lipid mediators, cytokines, and chemo-
kines. Released histamine and lipid mediators induce the
early allergic response considered to put the patient at risk,
whereas cytokines and chemokines contribute to the late
phase response and recruitment of other effector cells of the
allergic inflammation (e.g. basophils and eosinophils) [5, 6].
The study of human mast cells is challenged by the
difficulties of obtaining pure human mast cells. Several
human mast cell lines have been developed to get a high
number of human mast cells for functional studies [7, 8].
Even though human mast cell lines are useful for
investigating a general mast cell mechanism they cannot
be used for investigating the cellular difference between
allergic and non-allergic subjects. Human mast cells can be
isolated directly ex vivo from tissue, but often the yield is
insufficient for extended examination and the harsh
enzymatic treatment needed to disperse mast cell from
tissue may affect the functional characteristic as well as
having the disadvantage of tissue often being obtained from
patients undergoing surgical resection due to severe illness. A
more recent approach is to generate human mast cells in
vitro from hematopoietic stem cell isolated from peripheral
or umbilical cord blood using prolonged culturing with stem
cell factor (SCF), Interleukin 3 (IL-3) and IL-6 [9].
Peripheral blood-derived mast cells (PBdMC) resemble in
vivo human mast cells with respect to morphology,
metachromatic stain, FceRI and CD117 expression, hista-
mine release and secretion of chemokines and cytokines
upon activation [10, 11].
Human mast cell expresses many different cell surface
receptors enabling mast cells to balance the response to
various triggers. FceRI, C3aR, CD88, and CD48 are receptors
belonging to the adaptive and innate immune response,
respectively, and are described to result inmast cell activation
followed by the release of histamine and cytokines [12–15]. In
contrast, receptors are also found which suppress mast cell
activation. These receptors act by recruiting and activating
phosphatases that counteract phosphorylation in the intra-
cellular signaling cascade. Among these inhibitory receptors
are CD32, CD200R, CD300a, and siglec-8 [5, 16–18]. The
expression level of activating and inhibitory receptors is
important for the outcomeof themast cell response. A skewed
expression of these receptors might be involved in the
pathophysiology of allergic diseases.
Humanmast cells are known to release histamine after IgE-
mediated activation but some phenotypes of mast cells, for
example, skin mast cells, also respond to secretogeous such as
the anaphylatoxins complement 3a and 5a (C3a and C5a),
neuropeptides (e.g. Substance P) andbioactive chemicals (e.g.
Compound 48/80) [19]. Furthermore, human mast cells
secrete a very large panel of proinflammatory proteins upon
IgE-mediated activation permitting development and accel-
eration of the allergic inflammation. A unique selection of
secreted proinflammatory mediators might be found from
mast cells originating from allergic subjects.
Another factor which has the capability to influence which
productswill be releasedby themast cell ismicroRNA(miRNA).
This is a large class of small regulatory molecules capable of
controlling translation of target transcripts by binding to specific
messenger RNA (mRNA) molecules and repressing their
translation into functional protein products [20]. The role of
miRNAs in mast cell biology has become an area of research in
recent years but studies have mostly been conducted using mast
cells derived from rodents [21]. Only a few studies investigate
miRNA in primary human mast cells or human mast cell lines
and it is not known if mast cells from peanut allergic subjects
express a unique miRNA profile [22–24].
To our knowledge, PBdMCderived from food allergic and
non-allergic subjects has never been compared previously,
hence the aim of this study was to investigate if PBdMC from
non-allergic and peanut allergic subjects differ in the
molecular—(cell surface receptor expression) and func-
tional profile (histamine release, cytokine/chemokine secre-
tion and miRNA expression).
Methods
Study population
Peanut allergic patients were recruited from the Allergy
Clinic, Copenhagen University Hospital, Denmark based on
a positive oral food challenge tests or a convincing medical
history of severe immediate reaction to peanut and peanut-
specific IgE concentration above 3.5 kUA/l in serum. Non-
allergic participants tolerated peanut consumption and did
not suffer from any known allergy. The study conforms to
the standards of the declaration of Helsinki and was
approved by the committees on Health Research Ethics in
the Capital Region of Denmark (H-15001321). Written
informed consent was obtained from all participants. The 24
subjects included in this study were part of a cohort
consisting of 25 subjects who were also included in another
study [25]. One subject refused to participate in this study
due to anxiety to blood sampling. Six subjects were excluded
from the PBdMC study due to less than 90% purity of
PBdMC after seven weeks of culture. Some subjects yielded
an insufficient number of PBdMC to run all assays, thus the
specific number of individuals are indicated in each figure.
Mast cell differentiation
Two hundred milliliter whole blood was drawn from each
participant by venipuncture. Human mast cells were
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generated as previously described [9, 13]. In brief, peripheral
blood mononuclear cells were purified by lymphoprepTM
density gradient separation (Axis-Shield PoC, Oslo,
Norway) and CD34þ hematopoietic stem cells were isolated
from peripheral blood mononuclear cells by magnetic-
activated cell sorting using CD34 MicroBead Kit (Miltenyi
Biotec, GmbH, Bergisch Gladbach, Germany) according to
the manufacturer’s instruction. Enriched CD34þ cells were
cultured in StemPro1-34 medium (Invitrogen, Carlsbad,
CA) supplied with 100 ng/ml recombinant human SCF
(PeproTech, Rocky Hill, NJ), 100 ng/ml recombinant
human IL-6 (PeproTech), 100U/ml penicillin (Sigma–
Aldrich, St Louis, MO), 100mg/ml streptomycin and
2mM L-glutamine (Sigma–Aldrich). Recombinant human
IL-3 (30 ng/ml) (PeproTech) was included in the medium
for the first week only. After 7–8 weeks of culture, the
PBdMC were used for experiments. The purity of cultured
PBdMC was assessed by toluidine blue staining and flow
cytometry analysis and revealed >90% metachromatic
stained cells and CD117þFceRIþ cells.
IgE sensitization and anti-IgE stimulation of
cultured PBdMC
PBdMC were sensitized with 1mg/ml human myeloma IgE
(Calbiochem, Merck Chemicals, Beeston, Nottingham, UK)
per 400,000 cells for 18–24 hor left unsensitized (resting cells).
PBdMCwerewashed twicewithmedium to remove unbound
IgE. PBdMC were resuspended in medium (sensitized cells)
or medium added 1mg/ml goat anti-human IgE (KPL,
Gaithersburg, MD) (stimulated cells) and incubated at
378C for 1 and 18h. PBdMC were centrifuged at 500 g,
10min. Supernatantswere collectedand storedat808Cuntil
luminex multiplex analysis. Cell pellets were used for flow
cytometry (18 h incubated PBdMC) or stored at 808C for
miRNAarrays (1 h incubated PBdMC). For histamine release,
sensitized cells were used without any further incubation.
Flow cytometry analyses of surface receptors
PBdMC
Resting, IgE-sensitized and anti-IgE-stimulated PBdMC
were harvested and stained with Fixable Viability Dye
eFluor1 780 (eBioscience, San Diego, CA) for 30min at 48C.
PBdMC were then washed in PBS (Sigma–Aldrich) and
stained with anti-C3aR-AF647 (BD Biosciences, Franklin
Lakes, NJ), anti-CD88-PE-Cy5 (Biolegend, San Diego, CA),
anti-CD117-BV650 (BD), anti-CD124-AF700 (R&D Sys-
tems, Minneapolis, MN), anti-CD126-BV421 (BD), anti-
CD203C-BV510 (BD), anti-CD218a-FITC (Biolegend),
anti-FceRI-PE-Cy7 (Biolegend), anti-ST2-PE (R&D Sys-
tems), and anti-TSLPR-BV605 (BD) or stained with
anti-CD32-FITC (BD), anti-CD48-BV421 (BD), anti-
CD117-BV650 (BD), anti-CD172a-PerCP-eFlour
1
710 (ebio-
science), anti-CD200R-PE (Biolegend), anti-CD300a-AF647
(Novus Biologicals, Littleton, CO), anti-FceRI-PE-Cy7 (Biol-
egend) and anti-Siglec-8-AF700 (R&D Systems) for 30min at
48C. Cells were washed and acquired on a BD Fortessa flow
cytometer. Data were analyzed with FlowJo software version
10 (TreeStar, Ashland, OR). PBdMC were gated as viable
CD117þFceRIþ cells (Fig. S1). Receptor expression was
quantified using median fluorescence intensity of the specific
stain subtracted that of isotype-matched control (D MFI).
Basophils
Heparinized whole blood was drawn from all study
participants. Blood was diluted 1:1 (v:v) with RPMI 1640
(Sigma–Aldrich), added anti-C3aR-AF647 (BD), anti-CD3-
BV711 (BD), anti-CD14-APC-eflour780 (ebioscience), anti-
CD88-PE-Cy5 (Biolegend), anti-CD123-BV650 (BD), anti-
CD124-AF700 (R&D) anti-CD193-BV421 (BD) and anti-
CD294-PE-CF594 (BD) or stained with anti-CD3-BV711
(BD), anti-CD14-APC-eflour780 (ebioscience), anti-CD32-
FITC (BD), anti-CD123-BV650 (BD), anti-CD172a-PerCP-
eFlour
1
710 (ebioscience), anti-CD193-BV421 (BD), anti-
CD200R-PE (Biolegend), anti-CD300a-AF647 (Novus) and
anti-Siglec-8-AF700 (R&D Systems). Blood was incubated
with or without 1mg/ml polyclonal goat anti-human IgE
(KPL) for 30min at 378C using a water bath. Erythrocytes
were lysed with BD FACSTM lysing solution (BD). Cells were
washed and stained with anti-FceRI-PE-Cy7 (Biolegend) for
30min at 48C. Cells were washed, fixated using BDCellFixTM
(BD) and acquired on a BD Fortessa flow cytometer. Data
were analyzed as described above. Basophils were gated as
CD3-CD14-CD193þCD123þ cells (Fig. S2A).
Luminex multiplex
PBdMC secreted products were quantified using Procarta-
Plex Mix&Match 22-plex (ebioscience) according to the
manufacturer’s instruction. The assay measured; Eotaxin
(49), Eotaxin-3 (0.7), GM-CSF (13), IL-1beta (2.0), IL-4
(43), IL-5 (16), IL-8 (8.5), IL-10 (2.2), IL-13 (8.5), IL-18
(25), IL-22 (27), IL-23 (13), IL-31 (55), IL-33 (2.1), IL-37
(15), MCP-1 (4.7), MIP-1a (0.8), RANTES (1.1), TNF-a
(25), TSLP (2.2), VEGF-A (20), and VEGF-D (1.6), numbers
in parenthesis designate detection limit (pg/ml). The
samples were analyzed on a Bio-Plex 200 system using
Bio-Plex Manager 5.0 (BioRad, Berkeley, CA).
miRNA array
PBdMC pellets were lysed in 1ml TRIzol1 reagent
(Thermo Fisher Scientific, Waltham, MA), added 200ml
1-bromo-2 chloropropane (BCP) (Merck KGaA,
Mast cells from allergic and healthy subjects L. F. Larsen et al.
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Darmstadt, Germany), and centrifuged at 15,000g for
15min to separate the cell lysate in two phases. The BCP
top phase containing RNA was harvested, mixed 1:1 (v:v)
with phenol/chloroform (Thermo Fisher Scientific) and
centrifuged 15,000 g for 15min. The top phase was
harvested, mixed with phenol/chloroform again and phase
separated. This step was repeated until a distinct and
debris-free interface was visible. The top phase was
harvested and washed 1:1 (v:v) in BCP to remove phenol
residues. Extracted RNA was precipitated with ice-cold
isopropyl alcohol (Merck) 1:1 (v:v), centrifuged at 15,000g
for 15min, aspirated completely and washed in ice-cold
80% ethanol (Merck) at 15,000g for 5min. RNA pellet was
air-dried and dissolved in RNase-free H2O (Thermo Fisher
Scientific). Total RNA yield was determined spectropho-
tometrically measuring absorbance at 260 nm and relative
RNA purity was determined by calculating the ratio of
absorbance at 260 and 280 nm. More than 200 ng total
RNA/sample was labeled with biotin-3DNA1 conjugates
and run on GeneChip1 miRNA 1.0 array using Flash-
TagTM Biotin HSR RNA Labeling Kit according to the
manufactures’ instructions (Affymetrix, Santa Clara, CA).
miRNA array data were analyzed using the statistical
software R version 3.3.1 (R Core Team, Vienna, Austria).
Using package; Affy, mirna10cdf, annotate and gplot.
Histamine release assay
Sensitized PBdMC, kept in pipes buffer (RefLab, Copenha-
gen, Denmark) containing 0.5% (v:v) human serum
albumin (CSL Behring GmbH, Marburg, Deutschland),
were incubated for 1 h at 378C with polyclonal goat anti-
human IgE (KPL), Substance P (Sigma–Aldrich), Com-
pound 48/80 (Sigma–Aldrich), Complement 3a (R&D
systems), Complement 5a (R&D systems) or phorbol 12-
myristate 13-acetateþ ionomycin (both from Sigma–Al-
drich). PBdMC were centrifuged 300g, 10min and super-
natants harvested and transferred to glass fiber-coated
microtiter plates (RefLab, Copenhagen, Denmark) and
incubated at 378C for 30min. Released histamine was
detected using a fluorescence method (Reflab). In brief,
plates were washed repeatedly with demineralized water,
incubated with 0.4% SDS (RefLab) for 10min and washed
with demineralized water. Plates were incubated with
0.1mg/ml o-phthaldialdehyde (Reflab) at alkaline pH to
allow formation o-phthaldialdehyde:histamine fluorescent
complexes. After 10min the reaction was stopped by
decreasing pH with 0.59% perchloric acid and the
fluorescence intensity of each well were quantified on a
Histareader (Reflab). The measured fluorescence intensity
was converted to amount of released histamine using a
standard curve. The percentage histamine release was
calculated as: (released histamine of stimuli/maximum
histamine release induced by phorbol 12-myristate 13-
acetateþ ionomycin stimulation)  100.
Statistical analysis
The statistical analysis performed is written in the legend of
each figure. Significance was determined using a 2-sided a
level of 0.05. Statistical analysis was performed with
GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA).
Results
Characteristics of the study population
Ten peanut allergic and 14 non-allergic subjects participated
in the study. Four non-allergic and two peanut allergic
individuals were excluded from the PBdMC study as these
subjects did not yield pure cultures of PBdMC (<90%). The
characteristics of the resulting study population are shown in
Table 1. The age of the peanut allergic patients was
significantly lower than the non-allergic participants and
more peanut allergic patients presented with atopic
comorbidities compared to non-allergic individuals. All
peanut allergic participants had IgE to peanut and Ara h 2
above 5.4 and 4.1 kUA/l, respectively. None of the non-
allergic participants had detectable IgE to peanut and
Ara h 2.
PBdMC from peanut allergic and non-allergic
subjects have a comparable surface receptor
expression
To examine whether receptor expression differs between
PBdMC cultured from peanut allergic and non-allergic
subjects, PBdMC were left resting, sensitized with myeloma
IgE, or sensitized and stimulated with anti-IgE to mimic
allergen activation. PBdMC were gated as CD117þFceRIþ
cells (Fig. S1). Expression of CD124 (IL-4Ra), CD126 (IL-
6Ra), CD172a (SIRPa), CD218a (IL-18Ra), CD294
(CRTH2), thymic stromal lymphopoietin (TSLP) receptor,
and ST2 (IL-33R) were not detected on PBdMC (data not
shown). The expression of mast cells specific markers FceRI,
CD117, and CD203c did not significantly differ between
peanut and non-allergic allergic participants regardless of
whether the PBdMC were resting, sensitized or stimulated
(Fig. 1A–C). However, the expression of FceRI increased
following IgE sensitization and decreased to resting levels
after stimulation for both non-allergic and peanut allergic
subjects (Fig. 1A). CD117 expression decreased following
activation and the activation marker CD203c was as
expected elevated after anti-IgE activation (Fig. 1B and C).
The expression of receptors known to activate mast cell
and receptors able to inhibit/reduce mast cell activation were
L. F. Larsen et al. Mast cells from allergic and healthy subjects
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assessed to investigate whether the balance between
activation and inhibition differs among non-allergic and
peanut allergic subjects. Expression of innate immune
receptors capable of inducing mast cells activation (C3aR,
CD88, and CD48) did not differ between the two groups
(Fig. 1D–F) which was also the case for the inhibitory
receptors (Siglec-8, CD200R, and CD300a) (Fig. 1G–I). The
PBdMC were also positive for CD32 (Fig. 1J) however, since
the antibody used detects both CD32A, CD32B, and CD32C,
where only CD32B is inhibitory, it is not possible to correlate
the CD32 expression with an inhibitory capability. Lastly, a
generally reduced expression of CD48 and CD300a was
observed following 18 h of activation (Fig.3F and I). Overall,
PBdMC cultured from non-allergic and peanut allergic
individuals display very similar receptor expression profiles.
Basophil receptor expression was quantified on the entire
study population including subjects not yielding pure
PBdMC cultures. Expression of TSLP receptor, ST2,
CD218a, CD124, and Siglec-8 was not detected on basophils
(data not shown). Interestingly, basophils from non-allergic
and peanut-allergic subjects also expressed similar levels of
activation/potentiating receptors (CD88, CD123, CD193,
CD294, and C3aR) (Fig. S2). Only FceRI expression was
elevated in peanut-allergic subjects compared with non-
allergic individuals. This was expected as FceRI expression
correlates with total IgE level and the IgE level of peanut
allergic subjects was significantly higher compared to non-
allergic individuals (Table 1) [26–28]. Expression of
inhibitory receptors on basophils (CD172a, CD200R, and
CD300a) likewise did not differ between healthy and diseased
(Fig. S2). All basophils were also positive for CD32 (no
difference was observed between the groups) but even though
healthy basophils primary express CD32B, the ratio among
the three receptor subtypes might be different within the
allergic subjects. All in all, activating and inhibitory receptor
expression on both PBdMC and basophils did not discrimi-
nate non-allergic from peanut-allergic subjects.
Histamine release is comparable between peanut
allergic and non-allergic PBdMC
The degranulation capacity of PBdMC from non-allergic and
peanut allergic subjects was measured by histamine release to
a selection of secretagogues. IgE-sensitized PBdMC were
activated with anti-IgE, C3a, C5a, Substance P and
Compound 48/80. Anti-IgE and C3a activation elicited a
dose-dependent histamine release from all PBdMC and no
differencewas foundbetween non-allergic and peanut allergic
subjects (Fig. 2). PBdMC did not respond with histamine
release to C5a, Substance P or Compound 48/80 stimulation
which the human mast cell line LAD2 did (Fig. S3).
IL-31 is differently expressed in PBdMC from
peanut allergic subjects
The secretion of pre-stored and de novo sensitized
inflammatory mediators from IgE-sensitized and anti-
IgE-stimulated PBdMC were measured to investigate
whether the cytokine/chemokine secretion profile is altered
in subjects suffering from a peanut allergy. We found that
PBdMC can produce GM-CSF, IL-8, IL-10, IL-13, IL-23,
IL-31, IL-37, MCP-1, and VEGF (Fig. 3). PBdMC
supernatant did not contain detectable levels of Eotaxin,
Eotaxin-3, IL-1beta, IL-4, IL-5, IL-18, IL-22, IL-33, MIP-
1a, RANTES, TNF-a, TSLP, and VEGF-D. In general,
PBdMC secreted GM-SCF and IL-13 only following 18
hours of anti-IgE stimulation indication de novo produc-
tion of these cytokines upon FceRI activation (Fig. 3A and
B). VEGF was detected in PBdMC supernatant from both
sensitized and anti-IgE-activated cells, but only following
18 h of incubation (Fig. 3C). IL-8, IL-10, and MCP-1 were
continuously secreted from PBdMC and significantly
augmented production was detected following mast cell
activation (Fig. 3D–F). Of the nine detected cytokines, only
IL-31 was differently expressed between peanut allergic and
Table 1. Characteristics of the study population.
Demographic features Non-allergic (n¼ 10) Allergic (n¼ 8) P-value
Age (y) 25 (24–32) 20.5 (19–29) 0.04#
Female sex. no. (%) 7 (70) 7 (88) 0.59
Total IgE (kU/l) 37.7 (8.8–95.7) 463 (227–3419) 0.0014#
Specific IgE to peanut (kU/l) <0.35‡ 67.6 (18.5–90.2) <0.0001#
Specific IgE to Ara h 2 (kU/l) <0.35‡ 23.3 (19.3–36.0) <0.0001#
Other food Allergies. no (%) 0 (0) 5 (63) 0.0065
Urticaria. no. (%) 0 (0) 2 (25) 0.18
Atopic Eczema. no. (%) 0 (0) 8 (100) <0.0001
Asthma. no. (%) 0 (0) 5 (63) 0.0065
Rhinoconjunctivitis. no. (%) 0 (0) 8 (100) <0.0001
Values are shown as numbers (percentages) or medians (interquartile range). Statistics were done using Fisherś exact test or Mann–Whitney
U-test (#). ‡ designate below the detection limit for all non-allergic donors.
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non-allergic subjects. IL-31 secretion from PBdMC was
significantly increased following 1 h of activation from
peanut allergic subjects compared to non-allergic individ-
uals. However, the IL-31 concentration changed during
18 h of stimulation, with a tendency of PBdMC from non-
allergic subjects now having the highest concentration
(Fig. 3H).
miRNA array profile does not discriminate peanut
allergics from non-allergic subjects
miRNA arrays, detecting 847 miRNA sequences, were
performed to examine whether individual miRNAs are
differently expressed in PBdMC cultured from peanut
allergic and non-allergic subjects. In general, we did not
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Figure 1. Expression of cell surface receptors on resting and activated PBdMCs from non-allergic (n¼ 8–10) and peanut allergic (n¼ 7–8) participants.
PBdMC were harvested and incubated at 378C overnight with medium (resting cells) or medium containing human IgE to allow the cells to become
sensitized. PBdMC were washed and incubated at 378C for 18 h with (Stimulated) or without anti-IgE (Sensitized). PBdMC were then stained with anti-
FceRI-PE-Cy7 (AER-37(CRA-1)), anti-CD117-BV650 (104D2), anti-CD203C-BV510 (NP4D6), anti-C3aR-AF647 (hC3aRZ8), anti-CD88-PE-Cy5 (S5/1),
anti-CD48-BV421 (T€U145), anti-Siglec-8-AF700 (837535), anti-CD200R-PE (OX-108), anti-CD300a-AF647 (MEM-260) and anti-CD32-FITC (FLI8.26).
Statistics were performed using student t-test with Bonferroni correction for multiple comparisons. Comparing non-allergic with peanut allergic within
each condition (resting, sensitized, and stimulated) did not reach statistical signiﬁcance for any of the receptors. Gray bars¼ non-allergic, Black
bars¼ peanut allergic.
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Figure 3. Secreted products from sensitized and anti-IgE activated PBdMCs from non-allergic (n¼ 7–8) and peanut allergic (n¼ 7) participants after 1
and 18h incubation. PBdMC were harvested and incubated at 378C overnight with human IgE to allow cells to become sensitized. PBMCs were
incubated for 1 or 18 h with (þ) or without () anti-IgE (1mg/ml). Collected supernatants were analyzed using multiplex bead-based assay. Gray shaded
area indicates below detection limit. Gray circles; non-allergic subjects. Black triangles; peanut allergic patients. Black lines; medians. Statistics were
performed with Dunn's multiple comparison test. P values are shown above each comparison.
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Figure 2. Histamine release from cultured PBdMCs derived from non-allergic and peanut allergic participants. PBdMC from non-allergic and peanut
allergic subjects were sensitized with IgE for 18 h and stimulated with anti-IgE or C3a for 1 h. Gray circles; non-allergic (n¼ 10). Black squares; peanut
allergic (n¼ 6–7). Plotted as meanþ SD.
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observe distinct separation of sensitized and anti-IgE-
stimulated PBdMC with principal component analysis
(PCA) or significant up- or down-regulation of individual
miRNA transcript following anti-IgE activation (Fig. 4A and
B). Similarly, PCA plots comparing PBdMC derived from
non-allergic and peanut allergic subjects at sensitized or
stimulated state did not clearly separate the groups
(Fig. 4C and E). Lastly, no statistical significantly difference
was detected in individual miRNA expression between non-
allergic and peanut allergic subjects (Fig. 4D and F).
Differentially expressed miRNAs with a multiple compari-
son non-corrected P-value below 0.01 and more than 25%
difference in expression are listed in Table 2.
Discussion
We investigated whether cultured PBdMC discriminate
between non-allergic and peanut allergic subjects by
examining the expression of cell surface receptors, histamine
release mediated by different secretagogues, cytokine/
chemokine release followed by anti-IgE activation and
miRNA expression in resting and anti-IgE activated cells.
This thorough investigation of cultured human mast cells
did only reveal a molecular or functional difference in
expression of IL-31 in in vitro generated mast cells between
non-allergic and peanut allergic subjects.
PBdMC were cultured from mast cell progenitors found
in the circulation. Consequently, to detect cellular differ-
ences between peanut allergic and non-allergic subjects using
in vitro differentiated PBdMC, the dissimilarities should be
encoded already by the hematopoietic stem cells. Human
mast cells develop and fully mature in peripheral tissue
influenced by SCF and the local cytokine milieu [29]. In this
study SCF, IL-6 and IL-3 were used to develop PBdMC but
additional factorsmay be needed to fullymaturemast cells to
the state found in vivo. Thus, the phenotype of our PBdMC
might be different from the phenotype found in peanut
allergic subjects and therefore it is possible that the mast cell
phenotype could contribute to the development and the
pathologic mechanisms of allergic diseases. On the other
hand, ex vivo basophils from non-allergic and peanut-
allergic subjects were only different regarding FceRI
expression, explained by the difference in concentration of
circulating IgE, thereby arguing, that the effector cells of
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Figure 4. miRNA Arrays. miRNA arrays were run on resting and anti-IgE-stimulated PBdMCs from peanut allergic (n¼ 3) and non-allergic (n¼ 3)
subjects. A and B, PCA and Volcano plots when comparing miRNA expression between stimulated and sensitized PBdMCs. C and D, PCA and Volcano
plots when comparingmiRNA expression on sensitized PBdMCs between peanut allergic and non-allergic subjects. E and F, PCA and Volcano plots when
comparing miRNA expression on stimulated PBdMCs between peanut allergic and non-allergic subjects. PCA plots, blue text: non-allergic subjects, red
text: peanut allergic individuals. Volcano plots; blue asterisks: individual miRNAs, red line: Bonferroni-corrected statistical signiﬁcant level. Statistics were
performed using paired and unpaired studentś t-test.
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allergy may not display a diverse cellular molecular (and
functional) profile besides carrying allergen-specific IgE on
their surface. While this seems to disprove our initial
proposition, it may help focus future studies on biomarkers
of food allergy.
Previous studies have addressed whether PBdMC display
different molecular and functional characteristics among
healthy and subjects suffering from different atopic
diseases. One study showed that PBdMC generated from
healthy controls and patients with allergic asthma are very
similar regarding degranulation measured by CD63
upregulation [30]. Another study investigated PBdMC
from atopic eczema patient and observed higher total
histamine and tryptase levels, impaired expression of
fungal recognition receptor, and enhanced IL-6 secretion
after fungal stimulation from PBdMC obtained from
atopic eczema subjects compared to healthy controls.
However, the release of histamine, IL-6 and IL-8 was not
different following anti-IgE activation [31]. Thus, these
studies are consistent with our overall observation i.e.
secreted inflammatory mediators from progenitor-derived
mast cells are equivalent between atopic patients and
healthy individuals.
In this study, we found that PBdMC released histamine
upon anti-IgE and C3a activation but not following C5a,
Substance P or compound 48/80 stimulation. The lack of
response to substance P and compound 48/80 deviates
from previous studies on PBdMC [13, 32]. The discrep-
ancy may indicate the PBdMC generated from whole blood
contra buffy coat preparation display a less mature
phenotype or alternatively more resembles mast cells
from lung, tonsils, and colon as these mast cells likewise do
not respond to substance P and compound 48/80 [19].
When analyzing the released inflammatory proteins our
PBdMC secreted a large variety. Interestingly, PBdMC
from peanut allergic subjects seem to release more IL-31
during 1 h but tend to have the lowest level after 18 h
indicating that these PBdMC might actively take up IL-31
over time. We did not look for IL-31 receptor expression,
which could have revealed if PBdMC from peanut allergic
patients express more IL-31R and therefore has an elevated
uptake of this cytokine. It was also not possible to validate
the IL-31 production using another technical approach
due to lack of test material. Nevertheless, IL-31 is known to
be secreted from PBdMC and elevated production from
human mast cells has been reported in patients suffering
from myeloproliferative diseases and mastocytosis [33–35].
Similarly, IL-31Ra has been detected on PBdMC by
proteome analysis and is phosphorylated upon anti-IgE-
stimulation [36]. IL-31 has been associated with pruritus
as increased levels were reported in the skin of atopic
dermatitis patients with severe pruritus but also induced
profound itch in mice overexpressing IL-31 [37, 38]. All
the peanut allergic subjects included in this study had
atopic eczema but no information was obtained regarding
pruritus. On the other hand, it is possible that the
increased expression of IL-31 during 1 h of incubation is
due to the atopic eczema present in all the allergic patients.
Besides atopic dermatitis, IL-31 has also been shown to be
increased in nasal secretions following nasal allergen
challenge in allergic rhinitis patients [39]. However, it
has not been investigated if IL-31 is involved in food
allergy. Similarly, the role of IL-31 in mast cell biology is
currently unknown. Accordingly, the difference in IL-31
Table 2. Differentially expressed miRNAs with a non-corrected P-value <0.01 and >25% difference in expression.
Sensitized PBdMC Stimulated PBdMC
Stimulated vs. sensitized PBdMC Allergic vs. Non-allergic Allergic vs. Non-allergic
miRNA
Expression
change (%) P-value† miRNA
Expression
change (%) P-value† miRNA
Expression
change (%) P-value†
UP
hsa-miR-132 55 1.00 hsa-miR-149-3p 376 0.17 hsa-miR-92b-5p 39 1.00
hsa-miR-557 52 0.57 hsa-miR-208b 28 1.00 hsa-miR-603 37 1.00
hsa-miR-1283 51 1.00
Down
hsa-miR-641 31 1.00
hsa-miR-373 29 1.00
hsa-miR-532-3p 26 1.00
hsa-let-7b-3p 26 0.11
Statistics were performed using paired and unpaired student t-test. † Bonferroni corrected P values.
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secretion among peanut allergic and non-allergic subjects
after 1 h activation observed in this study needs to be
further investigated.
Among the inflammatory proteins, we did not detect in
supernatant from anti-IgE-stimulated PBdMC, were eo-
taxin, IL-5, MIP-1a, and TNF-a which previously have been
shown to be released from PBdMC [40]. Especially the
absence of IL-5 and TNF-a was unexpected as transcription
of their corresponding mRNAs do increase in PBdMC
following anti-IgE activation (unpublished results by LFL)
and both cytokines have been shown to be released from ex
vivo isolated humanmast cells [40–43]. The lack of detection
could be due to freeze-thawing of the harvested supernatant
or insufficient sensitivity of luminex multiplex assays
used to quantify secreted protein products from PBdMC,
which have previously been addressed and discussed
elsewhere [13].
In conclusion, we performed a thorough molecular and
functional profile of PBdMC from peanut allergic and non-
allergic subjects testing 893 parameters and only IL-31 was
found differently expressed. It is possible that in vitro
differentiated PBdMC may not exhibit the cellular patho-
physiological properties as of in vivo derived mast cells, but
we believe it is more likely that mast cells from peanut
allergic subjects are similar to healthy individuals. Allergic
diseases may hence primarily be caused by specific IgE
sensitization and sensitivity in the target organ towards the
released mast cell mediators rather than influenced by the
cellular properties of the mast cells.
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